Yuxiang Ma

10PUBLICATIONS
45CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 09, 2026
Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin-6: Analysis of the Phase 1/1b Trial.

|Aug 25, 2026
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.

|Jul 24, 2026
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

|Mar 04, 2026
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Huaqiang Zhou, Hongyun Zhao, Xue Hou

|Apr 22, 2025
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao

|Mar 14, 2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.

Yuxiang Ma, Yunpeng Yang, Yan Huang

Pageof 2

Frequent Collaborators

6 joint publications

Hongyun Zhao

5 joint publications

Li Zhang

3 joint publications

Hai Zhu

3 joint publications

Wenfeng Fang